PMID- 30035778
OWN - NLM
STAT- MEDLINE
DCOM- 20190617
LR  - 20190617
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 22
IP  - 4
DP  - 2018 Aug 1
TI  - Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of 
      Associated Adverse Events.
PG  - E103-E114
LID - 10.1188/18.CJON.E103-E114 [doi]
AB  - BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjugate that targets 
      CD30-expressing cells. OBJECTIVES: This article assesses the occurrence and 
      management of the most frequent and clinically relevant BV-associated adverse 
      events (AEs), with a focus on Hodgkin lymphoma and systemic anaplastic large cell 
      lymphoma trials, and shares practical tips that may help decrease occurrence and 
      severity. METHODS: Peer-reviewed literature was surveyed to collect safety data 
      from sponsored clinical trials of BV and to compile associated management 
      guidelines. FINDINGS: Peripheral neuropathy was the most common BV-associated AE 
      across clinical trials. Other clinically relevant AEs included neutropenia, 
      infection, and infusion-related reactions. Awareness of and preparedness for 
      these common BV-associated AEs and other less common but significant AEs will 
      help nurse clinicians and patients maximize the clinical benefit for patients 
      receiving BV.
FAU - Clifford, Kathleen
AU  - Clifford K
AD  - St. Luke's Mountain States Tumor Institute.
FAU - Copeland, Amanda
AU  - Copeland A
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Knutzen, Gregory
AU  - Knutzen G
AD  - City of Hope.
FAU - Samuelson, Ellen
AU  - Samuelson E
AD  - Seattle Genetics.
FAU - Grove, Laurie
AU  - Grove L
AD  - Seattle Genetics.
FAU - Schiavo, Karen
AU  - Schiavo K
AD  - Seattle Cancer Care Alliance.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunoconjugates)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects/*therapeutic use
MH  - Female
MH  - Hodgkin Disease/*drug therapy
MH  - Humans
MH  - Immunoconjugates/*adverse effects
MH  - Lymphoma, Large-Cell, Anaplastic/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Peripheral Nervous System Diseases/*chemically induced/*nursing
OTO - NOTNLM
OT  - adverse events
OT  - brentuximab vedotin
OT  - management
OT  - peripheral neuropathy
EDAT- 2018/07/24 06:00
MHDA- 2019/06/18 06:00
CRDT- 2018/07/24 06:00
PHST- 2018/07/24 06:00 [entrez]
PHST- 2018/07/24 06:00 [pubmed]
PHST- 2019/06/18 06:00 [medline]
AID - 10.1188/18.CJON.E103-E114 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2018 Aug 1;22(4):E103-E114. doi: 10.1188/18.CJON.E103-E114.